Czech National Bank Acquires 26,900 Shares of Abbott Laboratories $ABT

Czech National Bank grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 6.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 425,277 shares of the healthcare product maker’s stock after acquiring an additional 26,900 shares during the quarter. Czech National Bank’s holdings in Abbott Laboratories were worth $57,842,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Livforsakringsbolaget Skandia Omsesidigt boosted its position in shares of Abbott Laboratories by 14.6% during the 2nd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 49,436 shares of the healthcare product maker’s stock valued at $6,720,000 after acquiring an additional 6,300 shares during the last quarter. Sandy Cove Advisors LLC bought a new stake in shares of Abbott Laboratories during the 2nd quarter valued at about $212,000. FF Advisors LLC boosted its position in shares of Abbott Laboratories by 4.3% during the 2nd quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker’s stock valued at $259,000 after acquiring an additional 79 shares during the last quarter. Everpar Advisors LLC boosted its position in shares of Abbott Laboratories by 11.0% during the 2nd quarter. Everpar Advisors LLC now owns 4,423 shares of the healthcare product maker’s stock valued at $602,000 after acquiring an additional 437 shares during the last quarter. Finally, Arlington Trust Co LLC boosted its position in shares of Abbott Laboratories by 9.1% during the 2nd quarter. Arlington Trust Co LLC now owns 11,940 shares of the healthcare product maker’s stock valued at $1,624,000 after acquiring an additional 1,000 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of recent research reports. BTIG Research dropped their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Morgan Stanley boosted their target price on Abbott Laboratories from $127.00 to $137.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Evercore ISI boosted their target price on Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Leerink Partners started coverage on Abbott Laboratories in a research report on Monday, June 16th. They issued a “market perform” rating and a $143.00 target price for the company. Finally, Mizuho boosted their target price on Abbott Laboratories from $130.00 to $140.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 16th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Trading Down 1.7%

NYSE ABT opened at $131.40 on Tuesday. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23. The stock has a market cap of $228.70 billion, a P/E ratio of 16.47, a P/E/G ratio of 2.54 and a beta of 0.69. The stock’s fifty day moving average price is $130.36 and its 200-day moving average price is $131.21. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the prior year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at approximately $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.